Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 5, 2012

Apogenix Raises €7.5M to Progress Glioblastoma Drug Through Phase II

  • Apogenix raised €7.5 million in a financing round to support a Phase II study with its lead protein therapeutic candidate APG101 in the treatment of glioblastoma multiforme (GGM) and other potential cancer indications. Completion of the fundraising follows just two days after the German firm announced the award of a €2.3 million (over $2.99 million) federal German grant to support continued development of the CD95 ligand inhibitor as a potential treatment for myelodysplastic syndrome.

    “APG101 has great potential to treat glioblastoma patients, a disease with very few treatment options,” remarks Thomas Höger, Ph.D., Apogenix’ CEO and CFO. “Based on the Phase II GBM data, we will approach potential partners to explore their interest in the therapeutic and economic potential of APG101.”

    The €7.5 million financing round was led by dievini Hopp BioTech, which has been the main investor in Apogenix since its inception as a German Cancer Research Center spin out in 2005. Over the last six years Apogenix has raised over €50 million in financing, and been awarded public grants totaling over €8 million. 

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »